Why NeoGenomics, Inc. Stock Rocketed Higher

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of NeoGenomics (NASDAQ: NEO  ) , a cancer-focused provider of genetic and molecular testing services for hospitals, pathologists, and oncologists, soared by as much as 26% after reporting its second-quarter earnings results.

So what: For the quarter, NeoGenomics reported record quarterly revenue of $20.7 million, a 32% increase from the previous year, as test volume growth expanded 40% and the average cost to conduct each test dropped 12%. This helped boost NeoGenomics' gross profit margin by 360 basis points to 49.5% from the year-ago period and pushed its EBITDA up by nearly 16% to $2.1 million. Profit per share was unchanged, however, at $0.01 from the year-ago quarter. By comparison, the company's EPS results were in-line with its boosted June guidance of breakeven to $0.01, while revenue slightly topped its $20 million-$20.5 million forecast.

Looking ahead, NeoGenomics anticipates reporting full-year revenue of $83 million-$86 million on EPS of breakeven to $0.03. Wall Street, in contrast, was only expecting $80.7 million in full-year sales and a $0.02 per share profit.

Now what: Obscene valuation relative to its breakeven EPS potential aside, there's a lot to like about NeoGenomics' press release. Costs for its testing products are coming down, the company is ramping up hiring in the wake of its stronger top-line growth, and it's also dramatically reduced its days sales outstanding from 103 days to 83 days, meaning it's collecting more of its billed services quicker, which also will allow the company to expand and hire at a faster pace.

Most importantly, I believe NeoGenomics is placed in a niche position of a rapidly growing field: cancer research. Big pharma and biotech companies have demonstrated a willingness to spend research and development dollars on finding cures for cancer, and one of the most important steps within that process is diagnosis, staging, and therapeutic personalization for the patient, which is where NeoGenomics could play a key role. It's quite possible we could see this company grow its top-line by a double-digit percentage throughout the remainder of the decade, which certainly compels me to add this stock to my watchlist today.

NeoGenomics may offer plenty of potential, but the opportunity for growth with this revolutionary product could leave NeoGenomics eating its dust! 
The best health care investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3033286, ~/Articles/ArticleHandler.aspx, 9/4/2015 12:44:48 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated Moments ago Sponsored by:
DOW 16,081.90 -292.86 -1.79%
S&P 500 1,919.75 -31.38 -1.61%
NASD 4,678.70 -54.80 -1.16%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/4/2015 12:24 PM
NEO $6.38 Up +0.09 +1.36%
Neogenomics Inc. CAPS Rating: *